Therapeutic Response

EGFR TKD activating variants status confers therapeutic sensitivity to Gefitinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Iressa (gefitinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized gefitinib as a monotherapy treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating variants of EGFR-TK.